Company intelligence / Profile preview

Acucela Japan

Tokyo, Japan

Ownership: Private
Employees: ~1
Development stage: Other

Overview

Acucela's lead candidate emixustat, a VCM small molecule, reached Phase 3 for Stargardt disease (initiated Nov 2018); prior Phase 2 trials completed for proliferative diabetic retinopathy and Stargardt disease with announced results in 2018. Pipeline also includes device for neovascular retinal monitoring.[1][2]

Therapeutic areas: Ophthalmology
Modalities: Small molecule
Industry: Biotech

Partnerships

Otsuka Pharmaceutical Co., Ltd.SIRION Biotech GmbH

Beyond the preview

Go deeper on Acucela Japan.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acucela Japan.

Explore the full profile